Treatment of elevated intraocular pressure in the course of diseases such as ocular hypertension, chronic open-angle glaucoma (including glaucoma in patients with a lens-free eye).
Composition:
1 ml eye drops contain 5 mg of Timolol in the form of maleate (and 0,1 mg of benzalkonium chloride).
Action:
A non-selective β-adrenergic antagonist, devoid of intrinsic sympathomimetic activity, direct depressive action on the myocardium and local anesthetic effects. Does not affect or has little effect on accommodation and pupil diameter. In patients with cataracts, the use of the preparation avoids sight loss in the area of lens opacity due to miosis. Some patients have experienced reduced response to treatment during long-term use. The onset of action occurs 0.5 h after a single dose, the maximum effect within 1-2 h, the effect of the drug persists for 24 h.
Contraindications:
Hypersensitivity to the active substance, other β-blockers or to any of the excipients. Bronchial asthma (also in an interview), severe chronic obstructive pulmonary disease, sinus bradycardia, atrio-ventricular block IIst. or IIIst, symptomatic heart failure, cardiogenic shock.
Precautions:
Before starting treatment, heart failure should be compensated. Patients with severe heart disease should be monitored for signs of heart failure and control their heart rate. When timolol is used to lower the elevated intraocular pressure in a patient with closed-angle glaucoma, the pupil that narrows the pupil should be used at the same time. When changing from miotone-depressant to Timolol, refractory therapy may be required after resolution of the miosis effect. When taking beta blockers in patients with a history of atopy or severe anaphylactic reaction to a variety of allergens, there may be no response to the usual doses of adrenaline.
Pregnancy and lactation:
It can only be used during pregnancy if the potential benefits justify a potential risk. Timolol is excreted in breast milk; making a decision to stop breastfeeding or withdrawal from the drug must result from the assessment of the benefit of the drug for the mother.
Side effects:
Eye irritation (including burning and stinging), conjunctivitis, blepharitis, keratitis, eye dryness, decreased corneal sensitivity, tinnitus, visual disturbances (including double vision), refractive changes (associated in some cases with discontinuation of drugs that constrict the pupil ), ptosis, detachment of the vascular membrane after filtration, bradycardia, arrhythmia, hypotension, syncope, heart block, cerebrovascular episodes, cerebral ischemia, congestive heart failure, palpitations, cardiac arrest, edema, intermittent claudication, Raynaud's syndrome , cold of the hands and feet, bronchospasm (mainly observed in patients with pre-existing diseases accompanied by bronchospasm), respiratory failure, shortness of breath, cough, headache, weakness, chest pain, alopecia, psoriasis-like rash, exacerbation of psoriasis, reactions hypersensitivity (reaction of anaph Keywords: vaginal edema, urticaria, limited or generalized rash), dizziness, depression, insomnia, nightmares, memory loss, worsening of symptomsmyasthenia gravis, paresthesia, nausea, diarrhea, indigestion, dry mouth, weakness of libido, Peyronie's disease, systemic lupus erythematosus. Adverse reactions reported during the use of timolol maleate in the form of systemic preparations may be considered as potential side effects after the use of eye drops: atrio-ventricular block IIst.and third-century, sinoatrial block, pulmonary edema, worsening of arterial insufficiency, exacerbation of angina, vasodilatation, breathing noise, limb pain, decreased exercise tolerance, pruritus, sweating, exfoliative dermatitis, weakness, impaired concentration, worsening of dreams, vomiting, joint pain, impotence, difficulty passing urine, hyperglycemia or hypoglycemia, non-platelet purpura. Deaths have been reported as a result of heart failure or bronchospasm in patients with bronchial asthma.
Dosage:
Do not start treatment with Cusimolol 0.5%. Treatment should be initiated by eye drops containing a 0.25% solution of timolol. Dospojówkowo. Initially 1 drop of 0.25% timolol solution to the affected eye twice a day (morning and evening). If the reduction in intraocular pressure is unsatisfactory, increase the dose to 1 drop of 0.5% timolol solution to the affected eye twice a day. In order to achieve a stronger therapeutic effect, the preparation can be used with other medications that lower the intraocular pressure. However, the use of the preparation with other topical β-adrenergic drugs is not recommended. Approximately 4 weeks after the start of treatment, the intraocular pressure should be re-evaluated, as stabilization of the response to the preparation may take several weeks. If the reduction in intraocular pressure is satisfactory, the drug can be dosed once a day. If the patient is using another topical β-blocker, stop using it after the full dose on the previous day, and the Next day administer one drop of 0.25% timolol solution to the affected eye twice daily. If the response to treatment is insufficient, the dose can be increased to 1 drop of 0.5% timolol solution twice a day. Change from another anti-glaucoma drug that is not a β-blocker applied topically: on the last day of the anti-glaucoma treatment, start with a 0.25% solution of timolol one dose 2 times a day, discontinue the previously used medication the next day and continue treatment 0.25% thymolol solution. If necessary, use a 0.5% solution of timolol - 1 drop 2 times a day. Use in children is not recommended.
(C)
